We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $113M
1-Year Est. Return 245.92%
This Fund
S&P 500
This Quarter Est. Return
+16.04%
1 Year Est. Return
+245.92%
3 Year Est. Return
+826.04%
5 Year Est. Return
+770.7%
10 Year Est. Return
–
AUM
$113M
AUM Growth
-$10.7M
Cap. Flow
-$30.4M
Cap. Flow %
-26.9%
Top 10 Hldgs %
70.48%
Holding
39
New
12
Increased
2
Reduced
9
Closed
14

Top Buys

Rank Stock Value
1
TRAX
First Tracks Biotherapeutics
TRAX
+$5.31M
2
ASMB icon
Assembly Biosciences
ASMB
+$3.81M
3
AXSM icon
Axsome Therapeutics
AXSM
+$3.58M
4
NERV icon
Minerva Neurosciences
NERV
+$2.82M
5
KURA icon
Kura Oncology
KURA
+$2.74M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$10.6M
2
SLNO
Soleno Therapeutics
SLNO
+$6.7M
3
CMPS
Compass Pathways
CMPS
+$5.78M
4
TARS icon
Tarsus Pharmaceuticals
TARS
+$5.67M
5
OVID icon
Ovid Therapeutics
OVID
+$5.66M

Sector Composition

Rank Sector Weight
1 Healthcare 68.63%
2 Miscellaneous 31.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
26
Abivax
ABVX
$9.98B
– –
-33,712
Closed -$3.82M
CAPR icon
27
Capricor Therapeutics
CAPR
$550M
– –
-113,899
Closed -$3.46M
CMPX icon
28
CALL
Compass Therapeutics
CMPX
$432M
– –
-1,000,000
Closed -$5.29M
CMPS
29
Compass Pathways
CMPS
$1.81B
– –
-1,045,000
Closed -$5.78M
IKT icon
30
Inhibikase Therapeutics
IKT
$347M
– –
-1,325,000
Closed -$2.23M
KPTI icon
31
CALL
Karyopharm Therapeutics
KPTI
$41.3M
– –
-250,000
Closed -$1.39M
PRAX icon
32
Praxis Precision Medicines
PRAX
$9.85B
– –
-32,810
Closed -$10.6M
QURE icon
33
CALL
uniQure
QURE
$3.08B
– –
-300,000
Closed -$4.91M
REPL icon
34
CALL
Replimune Group
REPL
$1.42B
– –
-246,900
Closed -$1.89M
RLMD icon
35
Relmada Therapeutics
RLMD
$467M
– –
-210,525
Closed -$1.47M
SLNO
36
DELISTED
Soleno Therapeutics
SLNO
– –
-200,000
Closed -$6.7M
SLNO
37
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-200,000
Closed -$6.7M
TARS icon
38
Tarsus Pharmaceuticals
TARS
$3.7B
– –
-80,859
Closed -$5.67M
MAZE
39
CALL
Maze Therapeutics
MAZE
$1.46B
– –
-100,000
Closed -$2.98M
1
2

Similar funds

IA
Invested Advisors State College, Pennsylvania $113M AUM 23.72% 1-Year Est. Return
CPA
Clear Point Advisors Melville, New York $113M AUM 15% 1-Year Est. Return
MBC
Michael Brady & Co Westlake, Ohio $113M AUM
OCM
Objective Capital Management Pepper Pike, Ohio $113M AUM 22.81% 1-Year Est. Return
AWA
Ark Wealth Advisors Yorba Linda, California $113M AUM
TWS
Thomas W. Smith $113M AUM
OFP
OFC Financial Planning Short Hills, New Jersey $113M AUM 26.89% 1-Year Est. Return
IIM
IFC & Insurance Marketing Auburn, California $114M AUM

Ally Bridge Group's Q2 2026 Portfolio in Review

As of Q2 2026, Ally Bridge Group held 39 positions worth $113M, down 8.7% from $124M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Ally Bridge Group withdrew a net $30.4M in Q2 2026, closing 14 positions and reducing 9 holdings. Its most notable exit was Praxis Precision Medicines, an estimated $10.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 81% a quarter earlier, followed by Miscellaneous.

Against the trend, Ally Bridge Group opened a new position in First Tracks Biotherapeutics worth $5.72M.

  • Ally Bridge Group's largest Q2 2026 buy was First Tracks Biotherapeutics: 284,287 shares worth $5.72M.
  • Ally Bridge Group added most to Minerva Neurosciences in Q2 2026, an estimated $2.82M increase.
  • Ally Bridge Group's biggest Q2 2026 reduction was Ovid Therapeutics, cutting an estimated $5.66M.
  • Ally Bridge Group fully exited Praxis Precision Medicines in Q2 2026, selling an estimated $10.6M.
  • Ally Bridge Group's ten largest holdings make up 70% of its $113M portfolio in Q2 2026.
  • Ally Bridge Group opened 12 new positions and closed 14 in Q2 2026.
  • Ally Bridge Group's portfolio value fell 8.7% quarter-over-quarter to $113M.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.